PMID- 19168279
OWN - NLM
STAT- MEDLINE
DCOM- 20090514
LR  - 20181201
IS  - 1872-7980 (Electronic)
IS  - 0304-3835 (Linking)
VI  - 278
IP  - 1
DP  - 2009 Jun 8
TI  - Synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel in both androgen-dependent 
      and -independent prostate cancer cell lines.
PG  - 82-7
LID - 10.1016/j.canlet.2008.12.034 [doi]
AB  - To determine the synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel (PTX) 
      against prostate carcinoma (PC) cells by isobolographic analysis. We demonstrated 
      that DAC could significantly increase the susceptibility of PC cells to PTX, and 
      confirmed the synergy of DAC and PTX. DAC enhanced the PTX induced up-regulation 
      of caspase activity and antiproliferative effect, resulting in an increase of 
      cells in subG1 and G2/M phases. In addition, the synergy was observed in both 
      androgen-dependent and -independent PC cell lines. It suggested that combination 
      chemotherapy with DAC and PTX might be a new strategy to improve the clinical 
      response rate of PC.
FAU - Shang, Donghao
AU  - Shang D
AD  - Department of Urology, Beijing Friendship Hospital, Capital Medical University, 
      Beijing 100050, China.
FAU - Liu, Yuting
AU  - Liu Y
FAU - Liu, Qingjun
AU  - Liu Q
FAU - Zhang, Fengbo
AU  - Zhang F
FAU - Feng, Lang
AU  - Feng L
FAU - Lv, Wencheng
AU  - Lv W
FAU - Tian, Ye
AU  - Tian Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090124
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium)
RN  - 0 (Androgens)
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Tetrazolium Salts)
RN  - 776B62CQ27 (Decitabine)
RN  - EC 1.- (Oxidoreductases)
RN  - EC 3.4.22.- (Caspases)
RN  - M801H13NRU (Azacitidine)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Androgens/*physiology
MH  - Antineoplastic Agents, Phytogenic/pharmacology
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Apoptosis/drug effects
MH  - Azacitidine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Caspases/metabolism
MH  - Cell Cycle/drug effects
MH  - Cell Division/drug effects
MH  - Cell Line, Tumor
MH  - Decitabine
MH  - Flow Cytometry
MH  - Humans
MH  - Male
MH  - Mitochondria/enzymology
MH  - Oxidoreductases/metabolism
MH  - Paclitaxel/*pharmacology/therapeutic use
MH  - Prostatic Neoplasms/drug therapy/enzymology/*pathology
MH  - Tetrazolium Salts/metabolism
MH  - Up-Regulation
EDAT- 2009/01/27 09:00
MHDA- 2009/05/15 09:00
CRDT- 2009/01/27 09:00
PHST- 2008/10/25 00:00 [received]
PHST- 2008/12/05 00:00 [revised]
PHST- 2008/12/27 00:00 [accepted]
PHST- 2009/01/27 09:00 [entrez]
PHST- 2009/01/27 09:00 [pubmed]
PHST- 2009/05/15 09:00 [medline]
AID - S0304-3835(09)00008-1 [pii]
AID - 10.1016/j.canlet.2008.12.034 [doi]
PST - ppublish
SO  - Cancer Lett. 2009 Jun 8;278(1):82-7. doi: 10.1016/j.canlet.2008.12.034. Epub 2009 
      Jan 24.